Antengene Reports P-I/II (TORCH-2) Study Results of ATG-008 for the Treatment of Relapsed/Metastatic Cervical Cancer
Shots:
- The P-I/II (TORCH-2) study evaluating ATG-008 + toripalimab in 60 patients with relapsed/metastatic cervical cancer
- The results showed an ORR (52.4%) in the combination therapy & 77.8% for PD-L1+ patients & 1 out of 2 CPI-exposed patients reached PR with manageable side effects, similar to observations in prior global studies. The results were built from the early data from 21 patients, incl. 10 with PR & 1 with CR, 9 out of 10 were still responding, 2 with SD were still on treatment, m-PFS (5.5mos.)
- The (TORCH) study in patients with HBV+ unresectable HCC showed ORR (16.7%) in the 45mg/day dosing cohort; 3 with confirmed PRs out of 18 patients, m-DoR (4.3mos.), 2 out of 3 with PRs prior treated with PD-1/PD-L1 Ab
Ref: Antengene | Image: Antengene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
